Related Experiment Videos
[Approach to bronchial hyperreactivity in vitro].
1Département de Pharmacologie, CHU Pellegrin-Carreire, Bordeaux, France.
Therapie
|April 27, 1999
Summary
Interleukin 1 beta (IL-1 beta) potentiates bradykinin and tachykinin-induced human isolated bronchi contractions. This potentiation involves prostanoids, with mechanisms differing based on incubation time and agonist.
Area of Science:
- Pharmacology and Toxicology
- Respiratory Physiology
- Inflammation Research
Context:
- Asthma pathophysiology involves airway hyperresponsiveness.
- Isolated human bronchus models are crucial for studying drug-receptor interactions.
- Previous models have attempted to replicate asthma-like conditions in vitro.
Purpose:
- To investigate the effects of lipopolysaccharide (LPS) and interleukin 1 beta (IL-1 beta) on isolated human bronchi.
- To explore the mechanisms underlying IL-1 beta-induced potentiation of bronchus contractions.
- To determine the role of prostanoids, specifically thromboxane A2 (TxA2) and prostaglandin I2 (PGI2), in these responses.
Summary:
- Interleukin 1 beta (IL-1 beta) pre-treatment potentiated bradykinin and tachykinin-induced contractions in isolated human bronchi.
- These potentiated effects were abolished by indomethacin and the thromboxane A2 receptor antagonist GR 32191, indicating prostanoid involvement.
- IL-1 beta increased thromboxane B2 (TxB2) release, suggesting enhanced thromboxane synthase activity, and cyclooxygenase 2 (COX-2) activity for tachykinin-induced responses.
Impact:
- Demonstrates that IL-1 beta can enhance bronchus responsiveness to specific receptor agonists.
- Highlights distinct mechanistic pathways (thromboxane synthase vs. COX-2) involved in IL-1 beta potentiation.
- Provides insights into the inflammatory processes contributing to airway hyperresponsiveness in asthma models.